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Abstract
Recent case series describe detection of BK polyomavirus (BKV) in urinary tract cancers in 
kidney transplant recipients, suggesting that BKV could contribute to the development of these 
cancers. We assessed risk for urinary tract cancers in kidney recipients with or without treatment 
for presumed BKV nephropathy (tBKVN) using data from the United States Transplant Cancer 
Match Study (2003–2013). Among 55,697 included recipients, 2015 (3.6%) were reported with 
tBKVN. Relative to the general population, incidence was similarly elevated (approximately 4.5-
fold) for kidney cancer in recipients with or without tBKVN, and incidence was not increased in 
either group for prostate cancer. In contrast, for invasive bladder cancer, incidence was more 
strongly elevated in recipients with versus without tBKVN (standardized incidence ratios 4.5 vs. 
1.7; N=48 cases), corresponding to an incidence rate ratio (IRR) of 2.9 (95%CI 1.0–8.2), adjusted 
for sex, age, transplant year, and use of polyclonal antibody induction. As a result, recipients with 
tBKVN had borderline increased incidence for all urothelial cancers combined (renal pelvis, 
ureter, and bladder cancers: adjusted IRR 2.2, 95%CI 0.9–5.4; N=89 cases). Together with reports 
describing BKV detection in tumor tissues, these results support an association between BKV and 
urothelial carcinogenesis among kidney transplant recipients.
Introduction
Kidney transplant recipients have an elevated risk for cancer compared with the general 
population (1). Defective immune surveillance related to immunosuppressive medication use 
has been linked with an increased risk of virus-related malignancies, e.g., Epstein-Barr 
virus-related lymphomas, human papillomavirus-associated anogenital cancers, and human 
herpesvirus 8-associated Kaposi’s sarcoma (2). Kidney transplant recipients also have an 
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increased risk of developing some urinary tract cancers, including renal cell carcinoma, 
bladder cancer, and ureteric cancer (2–4). For unclear reasons, risk of prostate cancer is 
reduced among transplant recipients (1, 5).
BK polyomavirus (BKV, also known as human polyomavirus 1) can cause BKV 
nephropathy (BKVN) among kidney transplant recipients (6). Approximately 70–90% of 
healthy people are infected with BKV (6). BKV acquisition generally occurs in childhood, 
and the virus is thought to establish a lifelong chronic infection in the epithelium of the 
urinary tract. Intermittent asymptomatic low-level BK viruria in the range of 10–15% has 
been reported in immunocompetent individuals, but prospective screening studies suggest 
that 30–50% of kidney recipients develop BK viruria after transplantation, with a peak 
incidence in the first 2–12 months (6–8). Viruria sometimes progresses to viremia (usually 
after a gap of a few weeks), with a reported incidence of 5–15%. Although the progress to 
viremia closely mirrors the onset of BKVN, the incidence of biopsy-proven BKVN is 
reported to be only 1–5%, likely due to the focal nature of BKV disease (9–11). BKVN 
often leads to renal allograft loss, and a substantial body of literature exists about this 
association and its management (8, 12). Typical treatment regimens for BKVN involve 
reducing the level of immunosuppressive therapy. Rarely, BKV has also been associated 
with hemorrhagic cystitis or ureteral stenosis in kidney recipients (12).
BKV belongs to the polyomavirus family, other members of which have well-known 
oncogenic effects in rodents (7, 13). Some members of Polyomaviridae are associated with 
cancer in host animals ranging from mice to raccoons (14). BKV likewise causes various 
types of cancer, including nephroblastoma, in experimentally challenged rodents (13). Over 
the last few years, Merkel cell polyomavirus has been demonstrated to be the causative agent 
for the majority of Merkel cell carcinomas in humans (15). Notably, BKV has been linked to 
aggressive urinary tract cancers in kidney transplant recipients in a large number of recent 
case reports (16–34), as summarized by Papadimitriou et al. (35). These reports provide 
evidence of BKV in the tumors as demonstrated by immunohistochemical staining for BKV 
proteins, polymerase chain reaction (PCR) testing for BKV DNA, or detection of 
chromosomally integrated BKV through whole genome shotgun sequencing of the tumor.
Importantly, no population-wide studies have investigated the association of BKVN with the 
risk of developing urinary tract cancers. In this study, we used linked registry data from the 
United States to perform a detailed comparison of risk for post-transplant urinary tract 
cancers among kidney recipients with or without treatment for presumed BKVN.
Methods
The study cohort consisted of kidney transplant recipients (including recipients of other 
organs simultaneous with a kidney) in the Transplant Cancer Match (TCM) Study, a linkage 
of the US transplant registry (Scientific Registry of Transplant Recipients, SRTR) with 17 
state and regional cancer registries (see Table 1 note). The main exclusion criterion was 
missing information on the treatment for presumed BKVN (which we abbreviate “tBKVN”), 
as reported by transplant centers between 6 months and 2 years after transplant. Specifically, 
our analyses used the SRTR variable TFL_BK_THERAPY, which captures whether a 
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recipient was treated for BKVN (based on definitive or presumptive clinical information). 
Since data on tBKVN were first collected for transplants beginning in 2003, we excluded 
earlier transplants. Kidney recipients infected with human immunodeficiency virus were also 
excluded. Based upon these criteria, out of a total of 289,495 kidney transplants in the TCM 
Study, 55,697 were included in the analysis.
Urinary tract cancers (cancers of the kidney, renal pelvis, ureter, urinary bladder, prostate) 
were identified through linkage with the cancer registries. All invasive cancers at these sites 
(not merely first occurrences) were assessed. For bladder cancer only, we also assessed in 
situ cancers, because these are commonly diagnosed and ascertained by cancer registries.
Transplant recipients were classified according to the presence of tBKVN using the first 
reported value for TFL_BK_THERAPY in the interval of 6 months to 2 years post-
transplant. Follow-up for cancer started on the date of this report or start of cancer registry 
coverage, whichever occurred last. Because follow-up did not start until the reported value 
of TFL_BK_THERAPY, all cancer diagnoses occurred after ascertainment of tBKVN status. 
Patients were censored at death, failure of the transplanted kidney, subsequent transplant, 
loss of follow-up, or last date of cancer registry coverage (whichever occurred first).
We calculated the incidence of each urothelial cancer (defined as the number of outcomes 
per 1000 person-years of follow-up) in kidney recipients with and without tBKVN. We 
compared cancer incidence in kidney recipients to the incidence expected based on general 
population rates using standardized incidence ratios (SIRs). SIRs utilized general population 
rates stratified by sex, age, race/ethnicity, calendar year, and cancer registry. General 
population rates were obtained from data provided by participating cancer registries, except 
for Hispanics (which were not uniformly captured). For Hispanics, we obtained general 
population rates from Surveillance, Epidemiology, and End Results (SEER) cancer registries 
(https://seer.cancer.gov/). However, because SEER does not distinguish between in situ and 
invasive bladder cancer cases, SIR estimates excluded Hispanics when in situ and invasive 
bladder cancer were evaluated separately.
We also used Poisson regression to compare the incidence of graft failure due to BKVN or 
cancer among kidney transplant recipients according to tBKVN status as defined above. For 
cancer, we present unadjusted incidence rate ratios (IRRs) and results adjusted for potential 
confounders including sex, age, calendar year of transplant, and baseline induction 
immunosuppressive regimen. Because Poisson regression models did not require expected 
counts, we were able to include all transplants in the analyses of in situ and invasive bladder 
cancer.
We also conducted a sensitivity analysis that considered tBKVN to be present if there was 
ever a SRTR report of tBKVN, regardless of when it occurred after transplant or in relation 
to cancer diagnosis. This approach increased the sensitivity of ascertainment of tBKVN and 
the number of cancer cases considered to have tBKVN. However, it does not account for 
duration of time spent following tBKVN, and some tBKVN reports could have occurred 
after cancer diagnosis.
Gupta et al. Page 3
Am J Transplant. Author manuscript; available in PMC 2019 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
We also describe selected cancer cases in recipients with tBKVN. For bladder cancer cases, 
we report the tumor histology, grade, and stage at diagnosis. For kidney cancers, we describe 
whether cases arose in the native vs. donor kidneys based on a review of case documentation 
by cancer registry staff.
Results
Among 55,697 kidney recipients included in this study, 2015 (3.6%) had an indication of 
tBKVN in the period 6 months to 2 years post-transplant (Table 1). Although differences 
were not large, compared with recipients without tBKVN, recipients with tBKVN were 
more likely to be male (69.7% vs. 60.1%), elderly (age >65 years; 16.0% vs. 12.8%), and of 
non-Hispanic black race/ethnicity (26.1% vs. 22.5%). A large majority of patients received 
only a kidney (92.8% in both groups). Diabetes was more common as an indication for 
transplant among recipients without tBKVN (9.2% vs. 4.4%). Recipients with tBKVN were 
transplanted in more recent years than recipients without tBKVN (2010–2013: 23.7% vs. 
11.4%). As a result, recipients with tBKVN had shorter follow-up (mean 2.10 vs. 3.10 
years).
As also shown in Table 1, recipients with tBKVN were more likely to have received 
polyclonal antibody induction (51.8% vs. 41.3%). They were also slightly more likely to 
have received baseline maintenance immunosuppression with tacrolimus and/or 
mycophenolate (94.3% vs. 88.7%) and corticosteroids (72.7% vs. 69.7%). Mammalian 
target of rapamycin (mTOR) inhibitor use was more common in recipients who did not 
develop tBKVN (7.7% vs 2.3%). During follow-up, 173 (16.6%) recipients with tBKVN and 
327 (1.5%) recipients without tBKVN were reported to develop graft failure due to BKVN 
(unadjusted IRR 19.3, 95%CI 16.1–23.2).
A total of 584 incident cases of urinary tract cancers (including in situ bladder cancer) were 
identified in the study cohort (Table 2). When compared to the general population, incidence 
for kidney cancer was similarly elevated (~4.5-fold) in recipients with or without tBKVN, 
and incidence was not increased in either group for prostate cancer. Renal pelvis and ureteral 
cancers were rare (N=7 and N=2 total cases, respectively).
In contrast, for bladder cancer, including both invasive and in situ cases (N=80), incidence 
appeared more strongly elevated in recipients with tBKVN than in those without tBKVN 
(SIRs 2.1 vs. 1.4, Table 2). The SIR for invasive bladder cancer, in particular, appeared much 
higher in the recipients with tBKVN than in those without tBKVN (4.5 vs. 1.7). There were 
no cases of in situ bladder cancer in the recipients with tBKVN. In Poisson regression 
models in which all invasive bladder cancer cases were included, recipients with tBKVN had 
a higher incidence of invasive bladder cancer than those without tBKVN (adjusted IRR, 2.9, 
95%CI 1.0–8.2) (Table 3). As a result, there was also a borderline increase in incidence for 
all urothelial cancers as a group (renal pelvis, ureter, and all bladder cancers: adjusted IRR 
2.2, 95%CI 0.9–5.4).
The four invasive bladder cancers in recipients with tBKVN were all transitional cell 
carcinomas. One case described as having undifferentiated grade had spread regionally 
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beyond the bladder at the time of diagnosis. The other cases were diagnosed at localized 
stage and were described as being well differentiated, poorly differentiated, or of unknown 
differentiation, respectively. These four cancers were diagnosed at a median of 3.4 years 
(range 1.1–4.2 years) after tBKVN and 4.4 years post-transplant (range 1.8–5.1 years). The 
seven kidney cancers in recipients with tBKVN were described as renal cell carcinomas 
(N=3) or adenocarcinomas (N=4). Data on four of these cases were available with regards to 
the involved kidney. Two cases were bilateral, involving both native kidneys, and two were 
unilateral involving one native kidney.
Of the 327 recipients without tBKVN (based upon their first report during the 6-month to 2-
year window post-transplant) who were later reported to have graft loss due to BKVN, 157 
(48%) had at least one SRTR report during follow-up indicating positive tBKVN after the 
baseline assessment. In a sensitivity analysis that considered all follow-up reports of tBKVN 
regardless of timing, 9 recipients with tBKVN developed invasive bladder cancer, compared 
with 71 recipients without tBKVN (0.3% vs. 0.1%; p=0.05 by the Fisher exact test). No 
other cancer was associated with tBKVN in the sensitivity analysis (data not shown).
Discussion
BKVN is an important cause of long-term kidney allograft loss (6, 8, 12). Notably, BKV has 
also been linked to aggressive urinary tract cancers in kidney transplant recipients in case 
reports (35, 36). In our study, we aimed to provide results from a rigorous population-based 
study to examine the association of tBKVN in kidney recipients with subsequent risk of 
urinary tract cancers. We report that patients with tBKVN had an almost three-fold increased 
incidence for bladder cancers when compared with patients without tBKVN (adjusted IRR 
2.9, Table 3).
The association with bladder cancer in our study is consistent with previous case reports 
describing detection of BKV in 12 bladder cancer tumors from kidney transplant recipients 
(16, 18, 23–29, 31). Likewise, a recent single center study found a 12-fold elevated risk of 
bladder cancer in kidney transplant recipients with evidence of BKV-associated decoy cells 
in urine, BK viremia, or biopsy-proven BKVN (36). Of the 11 bladder cancers in the 
recipients with BKVN, four showed immunohistochemical evidence for the presence of the 
virus within tumor cells. Similar to these prior reports, the four bladder cancers seen in our 
tBKVN group were all invasive transitional cell carcinomas. In contrast to the somewhat 
frequent detection of BKV in bladder cancers from transplant recipients, BKV is present 
only rarely in bladder cancers that arise in the general population (34, 37). Among other 
urothelial cancers in transplant recipients, five additional cases of BKV detection have been 
described, including four of the allograft renal pelvis and, one involving the transplant ureter 
(17, 19–21, 30). Cancers of the renal pelvis and ureter were too rare to analyze separately in 
our study, but there was no indication of an association with tBKVN.
The incidence of kidney and prostate cancers was similar in our study between recipients 
with or without tBKVN. Although our results do not suggest the involvement of BKV in 
these cancers, other studies have reported the detection of BKV in cases of renal cell 
carcinoma (RCC) among transplant recipients. Two cases were poorly differentiated RCCs 
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and two were collecting duct carcinomas, one each of a native kidney and a transplanted 
kidney; additional details on the clinical and pathologic features of these cases are provided 
in the published reports (38–41). In our study, the four kidney cancers in recipients with 
tBKVN for which we had data were all diagnosed in the native kidney.
Case reports have used a range of methods to detect BKV in urinary tract cancers. Studies 
that used only PCR may have detected BKV only in adjacent or infiltrating normal cells, 
whereas use of immunohistochemistry can demonstrate that the virus is present in tumor 
cells. Using high-throughput sequencing of tumor DNA obtained from a urothelial 
carcinoma arising in a renal allograft, Kenan et al. demonstrated that BKV, similar to Merkel 
cell polyomavirus, can integrate into the human chromosome, which may lead to mutations 
within the viral non-coding control region that are important for oncogenesis (29, 30). In 
addition, the viral early genes (in particular, the large tumor antigen [LTAg]) can transform 
host cells in culture, primarily through inactivation of cellular tumor suppressor genes (7, 13, 
35). Of interest, Das and colleagues demonstrated LTAg expression in precancerous 
prostatic lesions (42). On the other hand, in a study examining the association of BKV with 
prostate cancer, although several cases were positive for BKV by PCR, none showed 
expression of the LTAg (43). These observations leave open the formal possibility that BKV 
LTAg expression might be transiently involved in early stages of the development of prostate 
cancer.
A strength of our study is that its population-based design captures data from a large fraction 
of kidney transplants performed in the US during 2003–2013. In addition, the linkage with 
cancer registries provided reliable data on incident cancers (44). We used the variable 
TFL_BK_THERAPY in the SRTR database to identify recipients with tBKVN. We assessed 
this at only one early point in time (6 months to 2 years post-transplant) to maximize 
subsequent follow-up, and because BKVN is usually an early diagnosis post-transplant (12). 
We also sought to optimize the reliability of the reporting, as later transplant center reports 
may less consistently capture clinical details.
Several factors support the validity of our assessment of BKVN status using tBKVN 
reported by the SRTR. First, the cumulative incidence of tBKVN in our study (3.6%) is 
consistent with results for BKVN reported in prior studies (1–5%) (8, 12). Secondly, 
recipients with tBKVN were more likely to have received T-cell depletion induction (51.8% 
vs. 41.3%) and less likely to have received mTOR inhibitors (2.3% vs. 7.7%) when 
compared with those without tBKVN. These observations are consistent with previous 
reports on this topic suggesting that T-cell depletion induction is strongly correlated with 
increased incidence of BKVN, and that mTOR inhibitor use might be protective (45). 
Thirdly, recipients with tBKVN were much more likely to progress to graft failure attributed 
to BKVN (unadjusted IRR 19.3, 95%CI 16.1–23.2). Our results also showed a similar 
association between tBKVN and bladder cancer in a sensitivity analysis in which we 
included all diagnoses of tBKVN regardless of when they were reported. We also observed 
an inverse association between diabetes mellitus and tBKVN, although published findings 
on the relationship between diabetes and BKVN have been variable (46, 47).
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There are also limitations to our study. Because of the relative rarity of tBKVN, the number 
of cancer cases expected in this group was small, which limited our ability to assess 
associations with less common cancers. In addition, recipients with tBKVN had relatively 
short follow-up (mean 2.1 person-years). The four bladder cancers observed in recipients 
with tBKVN occurred at a median of 4.9 years post-transplant, and many of the urothelial 
cancers observed in association with BKV in the literature have occurred later, e.g., at a 
median 5.9 years post-transplant (range 2–11 years) as summarized by Papadimitriou et al. 
(35). Thus, it is possible that we missed associations of tBKVN with urinary tract 
malignancies that will become apparent after longer follow-up. Finally, we were unable to 
capture asymptomatic BK viruria or viremia, so it is possible that we did not capture the full 
impact of BKV infection relevant for cancer.
To conclude, our results, when taken in conjunction with reports describing BKV detection 
in tumor tissue, support an etiologic role for BKV in urothelial carcinogenesis, especially 
with respect to bladder cancer. Our results confirm the rarity of urinary tract cancers even in 
patients with tBKVN but still underscore the need for clinicians to be aware of this 
association and focus on minimizing development of BKVN with careful prospective 
monitoring of BKV viremia and appropriate adjustment of immunosuppressive regimens. 
Finally, our results highlight the importance of ongoing research to understand mechanisms 
by which BKV could cause cancer and identify risk factors among patients with BKV 
infection for urinary tract cancers.
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BKV BK polyomavirus
IRR incidence rate ratio
LTAg large tumor antigen
mTOR mammalian target of rapamycin
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Table 1
Characteristics of Kidney Transplant Recipients with or without Treatment for Presumed BK Polyomavirus 
Nephropathy in the US Transplant Cancer Match Study
Characteristic
Recipients with
tBKVN
(% of total)
Recipients
without
tBKVN
(% of total) P-value
Total 2,015 (100.0) 53,682 (100.0)
Gender Male 1,405 (69.7) 32,242 (60.1) <0.0001
Female 610 (30.3) 21,440 (39.9)
Age at Transplant, years 0–34 402 (20.0) 11,238 (20.9) <0.0001
35–49 544 (27.0) 16,092 (30.0)
50–64 746 (37.0) 19,505 (36.3)
65+ 323 (16.0) 6,847 (12.8)
Race/Ethnicity White, Non-Hispanic 1,027 (51.0) 27,592 (51.4) <0.0001
Black, Non-Hispanic 526 (26.1) 12,086 (22.5)
Hispanic 321 (15.9) 10,308 (19.2)
Asian/Pacific Islander 141 (7.0) 3,696 (6.9)
Transplanted Organ Kidney 1,870 (92.8) 49,820 (92.8) 0.9975
Kidney and other 145 (7.2) 3,862 (7.2)
Reason For Transplant Glomerular diseases 556 (27.6) 14,259 (26.6) 0.3038
Hypertension 445 (22.1) 11,433 (21.3) 0.3973
Polycystic kidneys 174 (8.6) 4,815 (9.0) 0.6060
Diabetes 89 (4.4) 4,951 (9.2) <0.0001
Other 782 (38.8) 19,384 (36.1) 0.0133
Kidney Re-Transplant Retransplant 230 (11.4) 5,409 (10.1) 0.0505
Calendar Year of Transplant 2003–2006 638 (31.7) 30,032 (55.9) <0.0001
2007–2009 900 (44.7) 17,528 (32.7)
2010–2013 477 (23.7) 6,122 (11.4)
Induction Therapy Polyclonal 1,043 (51.8) 22,197 (41.3) <0.0001
Alemtuzumab 207 (10.3) 6,550 (12.2) 0.0092
Anti-IL2R 496 (24.6) 14,532 (27.1) 0.0148
Any induction 1,816 (90.1) 46,250 (86.2) <0.0001
Maintenance Regimen Tacrolimus and/or MMF 1,980 (98.3) 51,270 (95.5) <0.0001
Cyclosporine and/or azathioprine 91 (4.5) 4,656 (8.7) <0.0001
Maintenance mTOR inhibitor 47 (2.3) 4,137 (7.7) <0.0001
Maintenance corticosteroids 1,464 (72.7) 37,416 (69.7) 0.0046
Abbreviations: tBKVN: treatment for presumed BK polyomavirus nephropathy; IL2R: interleukin 2 Receptor; MMF: mycophenolate mofetil; 
mTOR: mammalian target of rapamycin.
The Transplant Cancer Match Study links data between the Scientific Registry of Transplant Recipients and 17 cancer registries (California, 
Colorado, Connecticut, Florida, Georgia, Hawaii, Iowa, Illinois, Kentucky, Maryland, Michigan, New Jersey, New York, North Carolina, Texas, 
Utah, and the Seattle-Puget Sound area of Washington).
*
Because the transplant was the unit of analysis, people with more than one transplant are included multiple times in the table. The median age at 
transplant for recipients with tBKVN was 51 years. For recipients without tBKVN, the median age at transplant was 49 years. All categories are 
mutually exclusive and exhaustive, so that sums are all equal to total number of transplants, except for reason for transplant. Because recipients 
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could have more than one reason for transplant indicated, p-values compare the recipients with and without tBKVN separately with respect to each 
reason.
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Table 2
Standardized Incidence Ratios for Urinary Tract Cancers among Kidney Transplant Recipients with or without 
Treatment for Presumed BK Polyomavirus Nephropathy
Cancer Recipients with tBKVN Recipients without tBKVN
N SIR (95%CI) N SIR (95%CI)
Kidney 7 4.5 (1.8–9.2) 228 4.6 (4.0–5.2)
Renal pelvis 1 13 (0.3–74) 6 2.5 (0.9–5.5)
Ureter 0 0 (0–86) 2 1.4 (0.2–5.2)
Bladder* 4 2.1 (0.6–5.4) 76 1.4 (1.1–1.7)
  Invasive 4 4.5 (1.2–12) 44 1.7 (1.2–2.3)
  In situ 0 0 (0–4.2) 24 0.9 (0.6–1.4)
All urothelial sites (renal pelvis, ureter, bladder) 5 2.5 (0.8–5.8) 84 1.4 (1.1–1.7)
Prostate† 6 0.6 (0.2–1.3) 254 0.9 (0.8–1.0)
Total 18 1.3 (0.8–2.1) 566 1.4 (1.3–1.6)
Abbreviations: tBKVN, treatment for presumed BK polyomavirus nephropathy; CI, confidence interval; SIR, standardized incidence ratio.
*
Bladder cancer cases include both invasive and in situ cancers, unless otherwise specified. SIR analyses for in situ and invasive bladder cancer 
separately exclude Hispanic recipients, because expected counts for these recipients could not be calculated. As a result, six cases of invasive 
bladder cancer and two cases of in situ bladder cancer in recipients without tBKVN could not be included in the SIR calculations for those 
outcomes.
†Analysis is restricted to males.
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